



G Medical Innovations Holdings Ltd  
ARBN 617 204 743

**ASX Announcement**

9 April 2020

## **CONTROLLED PLACEMENT AGREEMENT**

**G Medical Innovations Holdings Limited (ASX:GMV) (“G Medical” “the Company”)**, is pleased to advise that it has utilised its Controlled Placement Agreement (“CPA”) with Acuity Capital to raise \$1.475 million (inclusive of costs) by agreeing to issue 13,600,000 Shares to Acuity Capital at an issue price of \$0.1084.

This issue price represents a 5.2% discount to the 15 trading day VWAP of \$0.114 to 9 April (inclusive) and a small premium to the last closing share price of \$0.105. The funds raised will be used towards additional working capital with the Shares being issued out of the Company’s LR7.1A capacity.

The Company advises that the total capital provided under the CPA is now \$2.91 million.

The Company is also pleased to announce that Acuity Capital has agreed to increase the maximum amount of capital available under the CPA by an additional \$5 million and extend the expiry date of the CPA by 13 months. The maximum available capital under the CPA is now \$15 million with an extended expiry date of 31 January 2022.

As consideration for the above the Company has agreed to increase the shares held as collateral by Acuity Capital under the CPA to a total of 27 million through an additional issue of 13.4 million Shares out of its LR7.1 capacity (“Collateral Shares”). Though the Company may, at any time, cancel the CPA and buy back the Collateral Shares for nil consideration (subject to shareholder approval).

An Appendix 2A will follow.

**Ends**

**Authorised by CEO and Managing Director Dr Yacov Geva**

**Released through:** Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

### **About G Medical Innovations**

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit [www.gmedinnovations.com](http://www.gmedinnovations.com)

**About G Medical products:**

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.